A study to assess the effectiveness and safety of pacritinib in patients with VEXAS syndrome (PAXIS)
Scottsdale/Phoenix, AZ; Rochester, MN
The purpose of this stduy is to evaluate the efficacy of two dose levels of pacritinib compared to placebo during the double-blind treatment period in patients with VEXAS (i.e., Vacuoles in myeloid progenitors, E1 ubiquitin-activating enzyme, X-linked, autoinflammatory manifestations, and somatic) syndrome.